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Objectives: To critically examine the economic evidence on Cystic Fibrosis 
(CF) screening and to understand issues relating to the transferability of 
findings to the Australian context for policy decisions.  
Methods: A systematic literature search identified 25 economic studies with 
empirical results on CF published between 1990 and 2005. These articles were 
then assessed against international benchmarks on conducting and reporting 
of economic evaluations, focusing on the transferability of the evidence to the 
local setting.  
Results:  Six studies described only costs, 12 were cost-effectiveness studies, 6 
were cost-benefit studies and one had a combined design (cost utility, cost 
benefit and cost effectiveness). Most of the cost-effectiveness studies 
compared screening versus ‘no-screening’ but the screening programs under 
consideration differed markedly. Four considered neonatal screening, three 
prenatal screening, three pre-conception and carrier screening, and one 
considered all types of screening programs. The outcome measures also 
varied considerably between studies. One study included a quality adjusted 
life year measure. Cost–benefit measures mostly included economic savings – 
evaded lifetime medical costs of avoiding CF child birth.  
Conclusion: The variability in study design, model inputs and reporting of 
economic evaluations of CF carrier screening raises issues on the applicability 









1.  INTRODUCTION 
 
Cystic fibrosis (CF) is the most common serious genetic disease in Caucasians 
(Welsh,  Ramsey  et  al.  2001),  with  an  incidence  of  1  in  2500  and  carrier 
frequency of 1 in 25 (Massie, Delatycki et al. 2005).  Clinical manifestations 
include  progressive,  irreversible  suppurative  lung  disease  and  usually 
pancreatic  exocrine  insufficiency.    Most  children  with  CF  can  expect  to 
survive into adulthood, although the median life expectancy is in the late 30s.  
There is still no cure, the daily therapies are rigorous and there are many 
years of ill health as the suppurative lung disease progresses to death (Massie, 
Delatycki et al. 2005).     
 
Treatment  for  CF  pulmonary  diseases  has  improved  greatly  in  the  last  15 
years, but remains burdensome and expensive (Rowley, Loader et al. 1998).   
For  example,  some  of  the  newer  treatments  like  DNAse/Pulmozyme  and 
TOBI  have  been  shown  to  prolong  life  but  are  expensive  (A$15,000/per 
patient/per annum).   US studies report that the health care cost of treating 
CF is high with some studies estimating that the direct medical care costs of 
CF over a patient’s lifetime is around US$1.3 million (Rowley, Loader et al. 
1998).   This same study estimates that the indirect cost for parents caring for 
their children is equal to around $300k over the lifetime of a patient.    
 
In  Australia,  over  70  babies  with  CF  are  born  each  year  and  are  usually 
detected by newborn screening.  Almost all of these are to parents with no 
known  family  history  of  CF  (Massie,  Olsen  et  al.  2000).    Whilst  newborn 
screening  facilitates  the  early  diagnosis  of  CF  and  genetic  counselling  for 
affected  families,  organisations  such  as  National  Institutes  of  Health  (NIH 
Consensus Development Panel on Genetic Testing for Cystic Fibrosis 1999) 
and  the  joint  committee  of  the  American  College  of  Obstetricians  and 
Gynaecologists  and  the  American  College  of  Medical  Genetics  (American 
College of  Obstetrics  and  Gynecology  and  Genetics  2001) recommend that 
screening  tests  for  gene  mutations  that  cause  CF  should  be  offered  to  all 
pregnant couples and those planning pregnancy.   Preconception or prenatal 
CF carrier screening provides information to prospective parents and offers, 
in  part,  greater  reproductive  choices  in  the  event  that  both  parents  are 
carriers.   
 
Testing prospective parents for CF gene mutation carrier is reliable (Turner 
1998)  and  can  detect  nearly  85%  of  possible  severe  mutations  with  a  12 
mutation panel (Massie, Delatycki et al. 2005).  The test uses a painless cheek 
swab and costs are estimated to be A$100 for the single ∆F508 mutation and 
A$250 for the 12-30 mutations test (Christie, Zilliacus et al. 2006).   
 
Several  screening  strategies  have  been  evaluated  and  reported  in  the 
literature.  These  include  testing  couples  considering  have  a  child  at  the 
preconception  stage,  testing  couples  in  the  early  stages  of  pregnancy  or  
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testing  individuals  at  school  or  in  the  work  place.    In  addition,  there  is 
neonatal  carrier  screening,  where  newborn  children  are  tested  for  carrier 
status.    
 
With preconception screening, couples who are planning to have a child have 
a range of reproduction options available to them including, refraining from 
having (more) children, adoption, accepting the risk of giving birth to a child 
with CF, having prenatal diagnosis possibly followed by termination of an 
affected foetus  and  pre-implantation diagnosis.      In the  prenatal  screening 
strategy, pregnant women and their partners are screened as early as possible 
in their pregnancy.  Should both parents be found to be carriers, couples can 
choose  to  test  the  foetus  through  chorionic  villus  sampling  (CVS)  or 
amniocentesis.   If the foetus is diagnosed to be CF affected, parents can then 
choose  to  have  the  pregnancy  terminated.  In  planning  subsequent 
pregnancies,  CF  carrier  couples  have  the  same  range  of  options  as  those 
parents who underwent preconception screening (Wildhagen, Hilderink et al. 
1998).    
 
Screening options can be broadly characterised by (Morris and Oppenheimer 
1995): 
·  Timing (e.g. very early screening like for school-aged, while planning a 
pregnancy or during pregnancy) 
·  Model of screening (e.g. stepwise6 (or sequential), couple7 screening  or 
cascade’8 screening) 
·  Place  of  screening/by  whom  (e.g.  GP,  shared  care  GP,  obstetrician, 
public antenatal clinics, schools, workplace) 
 
In  Australia,  there  is  no  community  based  screening  program  for  genetic 
diseases.   The cost of implementing a screening program can be substantial 
but  international  studies  have  shown  that  screening  is  also  likely  to  bring 
substantial  benefits  to  prospective  parents  and  to  the  community  (Lieu, 
Watson et al. 1994; Hall, Viney et al. 1998; Rowley, Loader et al. 1998).   In an 
era of limited health care dollars, it is important to evaluate the potential costs 
as well as benefits to determine the extent to which a proposed CF carrier 
screening program provides value for money.   
 
The aim of this paper is to test the quality and transferability of the economic 
literature on carrier screening for cystic fibrosis.   Our focus is to determine 
whether the existing economic literature enables us to make evidence-based 
                                                 
6 With stepwise screening, women attending clinics are offered the test.   If a carrier is found, testing is 
offered to her partner after genetic counselling.   Carriers may suffer anxiety while awaiting their 
partner’s test result, but are informed of their individual risk status, which may be used to inform 
relatives or to allow new partners to be tested.   
7 Couple screening was devised to avoid carriers’ anxiety if the partner tests negative.   With this 
method, samples are taken from both partners and couples are given a positive result only if both are 
carriers.    
8Cascade screening is that in which the relatives of CF carriers are sought and tested.     
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recommendations to decision makers on the issue of CF carrier screening.   To 
do this we will firstly review the economic evidence, based on a systematic 
review of the peer-reviewed literature published between 1990 and 2005.  We 
will report the findings and examine the consistency of results.  Secondly, we 
evaluate  the  literature’s  strengths  and  weaknesses,  focusing  on  the 
transferability of existing evidence to the Australian setting.    
 
2.  METHODS: 
 
There are a number of screening strategies that can be employed to detect CF 
carriers (Wildhagen, Hilderink et al. 1998).   We have limited the scope of this 
review to community based preconceptional and prenatal screening.    This 
ensures that we are comparing the cost and consequences of similar types of 
programs.   
 
A systematic search on economic evaluations for cystic fibrosis on databases -  
EMBASE, MEDLINE and the NHS Economic  Evaluation DATABASE using 
keywords  ;  ‘cost,  cost-effectiveness,  cost  utility,  cost benefit,  cystic fibrosis, 
genetic screening’ was undertaken.  The abstracts were reviewed and studies 
that reported empirical evidence in English language published between 1990 
and  2005  were  retrieved.      References  of  the  retrieved  articles  were  hand 
searched for additional literature.   Excluded studies included non-systematic 
reviews,  correspondence,  editorials,  expert  opinions,  comments,  conference 
proceedings, non-English language articles.    Economic evaluation on CF was 
classified as those reporting ‘costs, cost-effectiveness, cost-utility, cost-benefit 
and their combinations’.  The economic evaluations eligible for review were 
described  and  appraised  in  terms  of  their  design,  methods,  outcomes  and 
costs  measures,  probabilities  reported,  key  results,  assumptions  and 
sensitivity  of  the  model  to  value  changes  in  variables,  limitations  and 
conclusions.   
 
To critically appraise the current literature, we developed a generic CF carrier 
screening decision-analytic framework to identify the data requirements for 
modelling  the  costs  and  outcomes  of  community-based  CF  screening 
programs.    Figure  1  and  Figure  2  illustrate  the  computational  needs  to 
develop  a  model  of  preconception  and  prenatal  carrier  screening, 
respectively,  compared  against  no  community  screening.      These  generic 
decision trees were developed using the pathways as reported in literature.  
The data requirements were subsequently identified as: 
 
1.  Consequence data 
·  Underlying population incidence of CF gene mutation 
·  Acceptance and uptake of carrier screening test (preconception and 
prenatal)  
·  Prenatal diagnosis acceptance rate  
  4
·  Preconception  reproductive  decisions  of  couple  at  risk 
(preconceptional) 
·  Post-conception  reproductive  choices  (termination  rates  , 
replacements and delivery (preconception and prenatal) 
·  Test  sensitivity  and  specificity  (CF  carrier  detection  and  foetal 
diagnosis tests).   
 
2.  Cost data 
·  Pre-screening  test  stage  (mass  communication,  personal 
information; 
·  Screening test stage (cost of organization and acquisition of sample, 
patient costs for testing, cost of test); 
·  Post-test stage (notification of results, cost of counselling, diagnosis, 
termination) and  
·  Lifetime costs of care.   
 
We  then  examined  the  literature  to  assess  to  what  extent  the  information 
contained in  these studies  could  be used to complete  the decision-analytic 
model  that  we  developed.      We  tested  the  quality  and  consistency  of  this 
evidence  and  hence  the  validity  of  transferring  this  information  from  one 
setting to another on the basis of standard recommendations (Drummond, 
O'Brien et al. 1997).   
 
3.  RESULTS: 
 
3.1  Economic evidence on CF carrier screening 
 
Searches yielded a total of 196 published articles.  After exclusion and hand 
searches,  25  economic  studies  with  empirical  results  on  cystic  fibrosis 
published between 1990 and 2005 were included in the review.   Twelve of the 
retrieved articles were from North America, 11 from Europe and one each 
from Australia and Israel.  Five studies were published between 1990-1994, 13 
between 1995-1999 and 7 between 2000 -2005.  Six studies reported costs only, 
10 reported only cost-effectiveness results, 7 reported only cost-benefit (net 
savings) results, and 2 used a combined design (cost effectiveness, cost benefit 
and/or cost utility).  Only 14 studies focussed on preconception or prenatal 
screening.  The remaining studies focussed on new-born screening for CF or 
predominantly reported the cost of care of patients with CF.   
 
Table  1  provides  a  summary  of  the  peer-reviewed  economic  literature  on 
preconception  screening  versus  ‘do  nothing’.      Most  studies  report  their 
findings  using  multiple  outcome  measure  and  screening  interventions  and 
each  of  these  were  compared  to  the  ‘do  nothing’  base  case.      To  enable 
comparison between studies, we have grouped findings by outcome measure 
and by type of screening intervention.   For each cost-effectiveness analysis 
(CEA), the table also shows the actual Incremental Cost-Effectiveness Ratio  
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(ICER) as reported in the study as well as a converted ICER that adjusts prices 
to 2005 levels using national price rise data and converted all currencies to 
US$  using  purchasing  power  parity  (PPP)  exchange  rates.      Studies  that 
examined the cost and benefits of CF screening reported their results in terms 
of whether there were any ‘net savings’ as a result of a CF carrier screening 
are also presented in Table 1.  Net savings was the term used in the literature 
and indicated whether the cost of screening would be offset by the potential 
medical care savings that could be averted if fewer babies with CF were born.  
Those studies that reported savings to be greater than costs are marked by a 
‘yes’ and where costs outweighed savings are marked by ‘no’.  We have not 
reported the monetary values of these because they were largely driven by 
the size of the program – making the results harder to compare. 
 
For the CEA studies, Table 1 shows wide ranging ICER even when comparing 
studies with (1) identical outcome measures, (2) similar types of interventions, 
(3) identical base case scenarios and (4) after adjusting for price levels and 
exchange rates.  The table also shows that numerous outcome measures were 
used, with the most common measure being the cost per carrier couple detected, 
followed by the cost per CF birth averted.  One study estimated the cost per 
quality adjusted life-year.   
 
Three studies, all set in the Netherlands, examined whether preconception CF 
carrier screening would result in net savings to society (Wildhagen, Hilderink 
et al. 1998; Verheij, Wildhagen et al. 1999; Weijers-Poppelaars, Wildhagen et 
al. 2005).   Two of these studies, indicated that step-wise carrier screening may 
result in net savings (Wildhagen, Hilderink et al. 1998; Verheij, Wildhagen et 
al. 1999) but one study reported that such an intervention would result in a 
net cost to society (Weijers-Poppelaars, Wildhagen et al. 2005).  It should be 
noted that these studies only took into account the cost and savings to the 
health system and did not attempt to measure wider impacts (eg, social costs, 
productivity losses, etc).   
 
Table 2 provides an overview of ten peer reviewed economic evaluations that 
have studied the cost and cost consequences of prenatal CF carrier screening.   
Once  again,  for  those  studies  that  conducted  a  CEA,  there  was  a  large 
variation  in  the  ICER.      Similar  to  the  ‘preconception’  studies,  the  most 
common outcome measures were cost per carrier couple detected and cost per CF 
birth  averted.    The  one  CUA  assumed  that  couples  who  terminated  a 
pregnancy  will  have  a  healthy  ‘replacement’  child  (Rowley,  Loader  et  al. 
1998).   The gain in QALY’s was then estimated by comparing the difference 
in the quality of life of a patient with CF with that of a healthy ‘replacement’ 
child as well as the gain in the quality of life of the parents.   
 
Seven studies reported their outcome in terms of ‘net savings’ by subtracting 
the cost of screening from the potential health care costs averted through the 
birth of fewer patients with CF.   Three studies reported that under their ‘base  
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case’ scenarios step wise screening would result in net savings and one study 
reported net savings for a couple screening program (Vintzileos, Ananth et al. 
1998; Wildhagen, Hilderink et al. 1998; Nielsen and Gyrd-Hansen 2002). Two 
studies  reported  that  prenatal  carrier  screening  could  result  in  additional 
costs to society (under their base case scenario) but in their sensitivity analysis 
savings were feasible under a plausible alternative scenario (Ginsberg, Blau et 
al. 1994; Rowley, Loader et al. 1998).   A further two studies reported no net 
savings but it should be noted that one of these studies was conducted for a 
population where the incidence of CF carrier status was low (compared to the 
Caucasian population) (Lieu, Watson et al. 1994; Doyle and Gardner 2003).   
 
Tables 1 and 2 demonstrate that there are only limited number of studies and 
these have delivered wide ranging ICER and inconsistent net savings results – 
although it should be noted that more studies support the notion that prenatal 
carrier screening may deliver net savings to society.   What is clear from this 
overview  of  the  economic  literature  is  that  it  offers  decision  makers  with 
limited information  and  considerable  uncertainty over the  cost-benefit  and 
cost-effectiveness of such programs.   It is therefore worthwhile considering 
how we could use the existing evidence in a different way to help form some 
recommendations for decision makers.   
 
The next section will examine the literature in more detail, focusing on the 
economic model inputs used and examining the strengths and weaknesses of 
this evidence for the purpose of developing our own decision-analytic model 
that is relevant to the Australian health care setting.   
 
3.2  Critical appraisal of literature for decision framework  
 
Table  3  provides  an  overview  of  the  reproducibility  assessments  for  14 
economic  studies  on  preconception  and  prenatal  studies.    All  the  studies 
clearly  reported  the  intervention  but  only  five  adequately  described  the 
comparator intervention – although in all cases it could be ascertained that the 
comparator  was  ‘no  screening’.      Eight  studies  indicated  that  a  societal 
perspective  was  used;  however,  six  of  them  actually  took  a  health  sector 
perspective. For example, all studies calculating the cost of CF care included 
direct  medical  care,  but  only  two  studies  included  patient’s  time,  indirect 
care, and parental work loss.   
 
There  were  important  differences  between  studies  in  the  way  cost  were 
estimated.  Eleven studies used a micro-costing approach, two used cost data 
from published literature and macro-costing approach was employed by two 
studies (one in combination with micro-costing).  In some cases there was 
inadequate reporting of costs.  For example, in some studies there was no 
indication  whether  the  estimated  cost  of  screening  included  variables  like 
information, counselling or notification of results.   
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Nine studies used discount rates for discounting future costs (or cost averted).  
The discount rates varied between 3 – 5%.  All the studies used sensitivity 
analysis to check for robustness.  However, there were differences in the type 
of sensitivity analysis used (univariate, bivariate, multivariate and threshold 
analysis).  The most common approach was univariate analyses.   Univariate 
analysis was used in 12 studies as standalone approach or in combination 
with bivariate/multivariate.   
 
3.2.1  Consequence data 
 
Probabilities on acceptance/uptake  
Preconceptional Screening: The reported participation rates for preconception 
screening ranged from 10% to 100%.   Uptake rates for screening strategies 
such  as  encouraging  patients  in  GP  surgeries,  group  educational  sessions, 
work  place  screening,  and  GP  invitations  do  not  yield  high  uptake  rates.  
Participation rates for school based CF screening programmes show uptake 
rates of up to 80% amongst the Jewish population but as low as 30% in other 
groups.  An Australian study reported high uptake rates in school screening 
(42- 75%) relative to other screening programmes (Wake, Rogers et al. 1996).   
 
Prenatal  Screening:  In  the  economic  literature  reviewed  here,  women’s 
participation in prenatal screening ranged between 50% – 100% (Table.  4b). 
Further,  studies  used  a  high  partners  acceptance  rate  (85-  100%)  in  their 
modelling.  Widespread variation in participation rates has a large impact on 
the eventual outcome of the economic study (Verheij, Wildhagen et al. 1999).   
For example, the cost per QALY of US$18,628 (20% uptake) reduced to US$ 
5,782 (100% uptake) among pregnant women.   The variation is even larger 
when the uptake of their partners increases from 50% (US$29,721) to 100% 
(US$3,693) (Rowley, Loader et al. 1998).   
 
Despite the widespread variation in participation rates used in the economic 
literature, most studies claim to have used empirical evidence.   The variation 
in  uptake  rates  are  not  explained  explicitly  in  the  reviewed  economic 
literature but other studies have indicated that variations may be explained 
by  differing  approaches  screening,  religious  beliefs  which  may  include 
opposition/reluctance  to  pregnancy  termination,  risk  perceptions,  and  the 
presence  or  absence  of  a  family  history  of  CF        Furthermore,  in  some 
countries, genetic information may add to the (actual or perceived) risk of 
losing health insurance (Decruyenaere, Evers-Kiebooms et al. 1998)  
 
Foetal Diagnosis 
Once  a  carrier  couple  has  been  identified,  they  can  choose  to  conduct  a 
prenatal diagnosis of foetus via CVS or amniocentesis.  For the preconception 
screening studies, the economic literature used participation rates of 75 – 85% 
(Table 4c).  Sensitivity analysis (range 60 – 90%) indicates that probability of 
foetal diagnosis has a large effect on the cost-savings balance for screening  
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programs  (Weijers-Poppelaars,  Wildhagen  et  al.  2005).        In  the  case  of 
prenatal screening, the uptake of foetal diagnosis ranged from 75 – 100%.   
 
The ICER was sensitive to the uptake prenatal diagnosis (Ginsberg, Blau et al. 
1994; Lieu, Watson et al. 1994; Rowley, Loader et al. 1998; Doyle and Gardner 
2003).  For example, with 50% prenatal diagnosis, cost per QALY of US$26,953 
reduces significantly to US$1,955 (with 100% uptake on prenatal diagnosis).  
 
All studies used low rates of spontaneous termination as a result of foetus 
diagnosis  (CVS:  0.  75  -  1.  3%  and  amniocentesis:  0.5%).    Foetal  losses  are 
believed to be somewhat higher in the first-trimester for CVS (1:100 compared 
to Amniocentesis 1: 250) (Vintzileos, Ananth et al. 1998).  Whilst the risk of 
spontaneous termination is low, the potential impact is high.   
 
Reproductive choices  
Preconceptional: Data (Table 4c) on the reproductive choices made by carrier 
couples was sparse.  Studies reported assumptions (based on literature) that 
15 - 25% of carrier couples refrained from having children and assumed that 
the rest 75 -85% would make use of prenatal diagnosis.   None of the reviewed 
studies  reported  probabilities  on  other  decisions  like  in  vitro  fertilization 
using  preimplantation  genetic  diagnosis.      This  technology  is  potentially 
expensive but was largely ignored by the literature (see section on cost of post 
screening test below).   
 
The probabilities used by the economic literature were based on very small  
studies and could have been subjected to selection bias (Wildhagen, Hilderink 
et al. 1998; Verheij, Wildhagen et al. 1999; Weijers-Poppelaars, Wildhagen et 
al. 2005).   However, sensitivity analysis (range 10 – 40%) of CF carrier couples 
refraining  from  having  children  (25%  considered  in  the  baseline)  does  not 
have a high impact (Weijers-Poppelaars, Wildhagen et al. 2005).  
 
Once  as  CF  foetus  has  been  identified,  parents  are  faced  with  a  choice  of 
terminating the pregnancy. The termination rates used in the preconception 
studies ranged from 80 – 95%.   Two studies used a 90 – 100% interval in their 
sensitivity analysis but this did not have any impact on the economic results 
(Weijers-Poppelaars, Wildhagen et al. 2005).   However, it should be noted 
that this a fairly narrow range and a lower termination rate may have shifted 
the result.   Studies have also included values in the range of 0.50 – 0.75% for 
iatrogenic termination.    
 
Prenatal: Therapeutic termination ranged from as low as 30% (in one study) 
to as high as 100%9.  The low 30% for termination was taken from empirical 
surveys  of  the  attitude  of  pregnant  women  and  affected  families  (Lieu, 
Watson et al. 1994).   
                                                 
9 Most of the studies have assumed a 75% termination rates  
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Prenatal studies reported that sensitivity analysis around termination rates 
did affect economic results.   For example,   cost per QALY reduces from 
US$23,855  (50%  termination  rate)  to  US$364  (100%  termination  rate)  for 
prenatal screening programs (Rowley, Loader et al. 1998).  In another study, 
cost  per  CF  birth  averted  increased  exponentially,  with  the  most  rapid 
increase  below  40%  termination  rates  (Lieu,  Watson  et  al.  1994).      The 
variations  in  termination  rates  may be  culture specific  (Nielsen  and  Gyrd-
Hansen 2002). 
 
Test sensitivity and specificity (CF Carrier detection and foetal diagnosis) 
Table 4e reports the test sensitivity and specificity probabilities for CF carrier 
detection.    Although  most  of  the  studies  have  assumed  a  theoretical 
specificity value of almost 100% for CF carrier detection, one study in Israel 
has  assumed  it  to  be  99%  accounting  for  misclassification,  laboratory 
contamination and genotyping error (Ginsberg, Blau et al. 1994).  In most of 
the  studies,  test  sensitivity  was  sourced  from  published  literature  and  is 
above 85%.  Two  studies used high variations in test sensitivity for various 
ethnic groups, with values as low as 30% for Asians, 57% for Hispanics and 
high  values  of  94%  and  97%  for  native  American  and  Ashkenazi  Jews 
(Vintzileos, Ananth et al. 1998; Doyle and Gardner 2003).    
 
High test sensitivity was reported to provide more cost-effective results.   In 
one  sensitivity  analyses  the  cost  per  high  risk  pregnancy  identified  was 
$162,000  at  60%  test  sensitivity  and  this  reduced  to  US$73,000  at  90%  test 
sensitivity  (Lieu,  Watson  et  al.  1994).      Cost  per  QALY  decreases  from 
US$16,861 (75% test sensitivity) to US$4,909 (90% test sensitivity) (Rowley, 
Loader et al. 1998).   Using the right test sensitivity for the decision framework 
will thus depend on the population structure.    
 
The test sensitivity and specificity for foetal diagnosis was assumed as 100% 
accurate in all the studies.   
 
3.2.2  Cost Data 
 
Pre-screening test costs  
In our review the costs estimated for the pre-screening test stage include mass 
communication and information giving and pre-test counselling. 
 
Pre-screening  test  costs  like  mass  communication  varied  from  as  low  as 
US$35,205 (in school screening) to between US$296,978 - $561,660 for general 
population  (Verheij,  Wildhagen  et  al.  1999;  Warren  and  Anderson  2004; 
Weijers-Poppelaars, Wildhagen et al. 2005).   
 
All the reviewed preconception studies included mass communication as a 
cost factor  but  used  costs  data  from  other  mass  media  campaigns such  as  
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breast screening awareness and folic acid campaigns (Wildhagen, Hilderink 
et al. 1998; Verheij, Wildhagen et al. 1999; Weijers-Poppelaars, Wildhagen et 
al. 2005) rather than a specific CF campaign.  Only two of the prenatal studies 
included mass communication costs ranging from US$39,622 to US$262,318 
(Ginsberg, Blau et al. 1994; Wildhagen, Hilderink et al. 1998).   No information 
linked  the  cost  (or  intensity)  of  the  mass  communication  campaign  with 
subsequent participation rates.    
 
All the preconception studies included the cost of personal information (US$ 
1.77 to US$2.92 per invitation) (Verheij, Wildhagen et al. 1999) (Wildhagen, 
Hilderink et al. 1998) (Weijers-Poppelaars, Wildhagen et al. 2005).  In the case 
of the school based a study – a cost per school was included rather than a 
personal information cost (Warren, Anderson et al. 2005).   Only three (out of 
ten) prenatal studies included cost of personal information (range US$1 to 
US$4.5) (Morris and Oppenheimer 1995; Wildhagen, Hilderink et al. 1998).    
 
Only  two  preconception  and  three  prenatal  studies  reported  a  pre-test 
counselling  cost  between  US$4  to  US$34.5  per  person  and  US$457.54  per 
school  (Lieu, Watson et al. 1994; Nielsen and Gyrd-Hansen 2002; Warren, 
Anderson et al. 2005; Weijers-Poppelaars, Wildhagen et al. 2005).   
 
Cost of screening 
The cost estimated for the screening test stage are the cost of organising and 
acquiring the sample, patient costs for testing and the cost of the test. 
 
The cost of organisation and acquisition and cost per test was reported in all 
preconception  studies.    Cost  of  test  organization  and  acquisition  varies 
between US$1.62 to US$22.25 and US$1232/school (Verheij, Wildhagen et al. 
1999; Warren and Anderson 2004; Weijers-Poppelaars, Wildhagen et al. 2005).   
For the prenatal studies, only two studies reported cost of test organisation 
and acquisition (range US$10.5 to US$17.3) (Morris and Oppenheimer 1995; 
Wildhagen, Hilderink et al. 1998),  
 
Patient costs for testing (like time taken and transport) has been reported by 
three  preconception  studies  and  ranged  from  US$2.65  to  US$14  (Verheij, 
Wildhagen et al. 1999; Warren and Anderson 2004).   Three prenatal studies 
reported patient costs (range US$10.  95 to US$41.45) (Ginsberg, Blau et al. 
1994; Asch, Hershey et al. 1998; Wildhagen, Hilderink et al. 1998).    
 
All studies reported the cost per test and ranged from US$28 (Nielsen and 
Gyrd-Hansen 2002) to US$385 (Verheij, Wildhagen et al. 1999).   The main 
source  of  variation  was  the  use  of  the  less  expensive  single  mutation  test 
versus the multiple mutation test.   
 
Cost-effectiveness results were highly sensitive to the cost of screening test 
(Ginsberg, Blau et al. 1994; Lieu, Watson et al. 1994; Cuckle, Richardson et al.  
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1995;  Rowley,  Loader  et  al.  1998;  Nielsen  and  Gyrd-Hansen  2002).      For 
example, an increase from US$67.5 to US$202.78 resulted in an increase in the 
cost per high risk pregnancy identified from US$52,724 to US$168,986 (Lieu, 
Watson et al. 1994).   Rowley et al report that if the cost of a laboratory test 
falls from $182 to $122 or less, prenatal screening became a dominant option 
compared to no screening (Rowley, Loader et al. 1998).   
 
Costs of post-test stage (after care) 
The cost estimated for the post screening test stage are the cost of counselling, 
CF foetal diagnosis, and reproductive choices. 
 
Most studies included cost of counselling for carrier couples and non-carrier 
couples.   Again,  a wide variation was noted in the cost/couple ranging from 
US$17.2  to  US$1,188.5  (carrier  couple)  and  US$9  to  US$205  (non-carrier 
couples)  (Ginsberg,  Blau  et  al.  1994;  Warren  and  Anderson  2004;  Weijers-
Poppelaars,  Wildhagen  et  al.  2005).      This  variation  is  explained  by  the 
difference  in  inclusion  of  resources  used;  for  instance  the  high  cost  post-
counselling study included cost of clinical geneticist in addition to the cost of 
screening (transport, parking, loss of production for both partners) (Weijers-
Poppelaars, Wildhagen et al. 2005).    Two studies did not include any cost of 
counselling for either carrier or non carriers (Vintzileos, Ananth et al. 1998; 
Nielsen and Gyrd-Hansen 2002; Doyle and Gardner 2003) and further two 
only included counselling cost for a subsection of the screened population 
(Cuckle, Richardson et al. 1995; Asch, Hershey et al. 1998; Vintzileos, Ananth 
et al. 1998; Doyle and Gardner 2003).    
 
All studies reported the cost of CF foetal diagnosis and ranged from US$249 
to  US$2,120  (Asch,  Hershey  et  al.  1998;  Wildhagen,  Hilderink  et  al.  1998).  
These  estimates  were  from  a  variety  of  sources  including  the  literature, 
government  reimbursements,  and official hospital  tariffs,  consultation  with 
administrators, micro-costing, current procedural terminology and  trial data.  
Some  studies  used  a  broader  definition  of  the  cost  of  CF  diagnosis  and 
included the cost of microvillar intestinal enzyme analysis (Asch, Hershey et 
al.  1998),  karyotype  cytogenetic  testing  along  with  costs  of  labour,  raw 
materials,  depreciation  and  overheads  (Ginsberg,  Blau  et  al.  1994),  and 
‘packages’  –  including    genetic  counselling,  DNA  testing,  karyotype 
determination and alpha-fetoprotein determination (Vintzileos, Ananth et al. 
1998).   
 
None  of  the  studies  reviewed  conducted  a  sensitivity  analysis  of  cost  of 
prenatal diagnosis on the economic results.    
 
The  cost  of  reproductive  decisions  were  included  in  all  studies  but  most 
restricted  cost  considerations  to  the  cost  of  termination.    None  of  the 
preconception  studies  included  the  cost  of  IVF  although  one  prenatal 
screening study included this cost to account for carrier couples decision to  
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have a ‘replacement’ child following a terminated pregnancy.  This cost was 
estimated to be US$4696 (Rowley, Loader et al. 1998).    
 
Three other studies added the cost of prenatal diagnosis as a reproductive 
decision of preconceptional screening and ranged from US$1,206 to  US$2,120 
(Wildhagen, Hilderink et al. 1998; Verheij, Wildhagen et al. 1999).   All the 
studies  were  done  in  Netherlands  and  the  cost  source  were  the  Dutch 
reimbursement rates.   The cost of reproductive decisions was only reflected 
through parent’s decision whether or not to have a prenatal amniocentesis or 
CVC after being detected as carriers through preconception screening.   
 
Variation  in  termination  costs  ranged  from  approximately  US$206  to 
US$3,486  (Nielsen  and  Gyrd-Hansen  2002);  (Asch,  Hershey  et  al.  1998).  
Estimates  were  from  a  variety  of  sources  including  literature,  government 
reimbursements,  office  of  technology  assessment,    official  hospital  tariffs, 
consultation  with  administrators,  and  micro-costing,  and  from  trial  data.  
Some studies included the costs of miscarriage (Ginsberg, Blau et al. 1994; 
Asch, Hershey et al. 1998) and medical care costs after spontaneous abortion, 
with  variation in  the  first  and second  trimester  (Lieu,  Watson  et  al. 1994).   
Only  one  study  adjusted  medical  charges  to  account  for  the  difference 
between the fees and opportunity costs (Asch, Hershey et al. 1998).   
 
One  study  conducted  a  sensitivity  analysis  on  the  cost  of  termination  but 
found that it had very little impact on the ICER (cost per QALY) (Rowley, 
Loader et al. 1998).    
 
Cost of care for CF patients: 
The cost of care for CF patients was estimated all of the studies where these 
were relevant to the analysis.  Three studies did not report the CF care costs 
because the chosen outcome measure made the cost of CF care irrelevant (i.e. 
the  cost  per  carrier  detected).      The  estimated  life  time  cost  range  from 
US$29,388 to US$ 1,252,073 (Lieu, Watson et al. 1994; Rowley, Loader et al. 
1998).   Studies from the US, predominantly used lifetime costs of CF patients 
reflecting the NIH consensus estimate of US$1,085,700/patient (US$800,000 in 
1997) (Vintzileos, Ananth et al. 1998; Doyle and Gardner 2003) or the Office of  
Technology  Assessment  report  estimates,  ranging  between    $329,388  and 
$437,371 (Asch, Hershey et al. 1998; Lieu, Ray et al. 1999), which was inflated 
appropriately to the reference year.  One study from the US estimated CF care 
costs  through  personal  communication  with  organizations  like  the  CF 
Foundation (Rowley, Loader et al. 1998).  The Dutch studies estimated the life 
time costs between US$377,603 to US$820,509 per patient  and were primarily 
based  on  reviewing  medical  records  of  CF  patients  (including  home  care 
collected using a questionnaire) but did not include indirect costs such as lost 
earnings  (Wildhagen,  Hilderink et al.  1998;  Verheij, Wildhagen  et  al. 1999; 
Weijers-Poppelaars,  Wildhagen  et  al.  2005).    The  differences  were  largely  
  13
driven by the discount rates to estimate the present value of life time costs, 
ranging from 3- 5%.   
 
Life time costs of CF care were estimated in several ways.  Some studies used 
age groups to define resource intensity with lower age groups consuming less 
health  care  compared  to  higher  age  groups.    One  study  estimated  cost 
according  to  disease  severity  and  estimated  that  the  annual  cost  of  care 
among patients with mild disease was around $6,200 and increased to $43,300 
among  patients  with  severe  disease)  (Lieu,  Ray  et  al.  1999).    One  study 
calculated only respiratory tract infections (RTI) related costs (Menzin, Oster 
et al. 1996).    
 
There were variations among the cost items included.  Most studies included 
the  cost  of  hospitalisation,  clinic  visits,  antibiotics  and  laboratory  costs.  
Hospitalization and medication formed the major component (40-60%) of cost 
of medical care in most of the studies.  Some of the variation in costs could be 
explained by ‘practice patterns’ which was likely to vary across countries – 
especially  the  likelihood  of  hospitalization  and  mean  length  of  stay  in 
hospitals  (Menzin,  Oster  et  al.  1996)  as  well  as  whether  patients  received 
treatment as an inpatient or outpatient (Robson, Abbott et al. 1992).   Non-
hospital  costs  of  care  (domestic  help,  diet,  travelling,  medication,  special 
facilities) are reported to constitute 50% of the total (medical and non medical) 
lifetime costs of cystic fibrosis (Wildhagen, Verheij et al. 1996).   
 
A  study  that  used  regression  techniques  to  estimates  the  cost  of  CF  care 
reports large inter-individual variation in cost of care for patients with CF 
(Johnson, Connolly et al. 1999).   
 
Lifetime costs of care of a CF patient were reported to have an important 
influence  on  the  outcome  of  the  economic  analysis  (Weijers-Poppelaars, 
Wildhagen et al. 2005).   The higher the cost of care for CF, the lower the 
incremental cost of screening compared with no screening and the more cost-
effective the program.  For example, Lieu et al reports that at a lifetime cost of 
US$67,595  for  CF  care,  screening  program  cost  US$1,25,726  per  high  risk 
couple identified and US$2.16 million per CF birth averted.   However, when 
the lifetime costs of medical care was US$2.21 million, the screening program 
would save money from the health care payer’s perspective (Lieu, Watson et 
al. 1994).    
 
4.  DISCUSION  
 
This overview of the evidence on the costs and consequences of community 
CF  carrier  screening  has  shown  widespread  variation.    The  ICER  varied 
significantly  even  after  adjusting  for  evaluation  timing  and  using  PPP 
exchange rates and comparing similar interventions and comparators.  
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On the basis of our overview, it is difficult to make any (economic) evidence-
based recommendations about whether or not a CF carrier screening program 
should  be  undertaken.      On  economic  grounds,  only  those  studies  that 
reported net savings can help us determine whether a CF carrier screening 
should be implemented or not.   Yet, the studies that reported net savings 
showed inconsistent results.     Furthermore, and perhaps more importantly, 
these studies use (and the results are largely driven by) potential offsetting 
‘savings’  in  health  care  costs  through  CF  births  averted.      This  is  a  very 
‘narrow’ view of the potential benefits of screening (Hall, Viney et al. 1998).   
In essence, it means that the value of a patient with CF is measured solely in 
terms of their health care costs.  Furthermore, it ignores the potential benefits 
(and harms) that the information provided by these tests can offer prospective 
parents.    
 
Rowley et al (Rowley, Loader et al. 1998) analysed the impact of screening 
slightly more broadly in terms of QALYs.   This study found that the cost per 
QALY  was  very  low,  indicating  that  program  represented  good  value  for 
money  when  compared  to  other  preventive  programs  (e.g.,  newborn 
phenylketonuria screening, mammography screening).   However, to generate 
a  difference  in  the  number  of  QALYs  between  the  screen  and  non-screen 
groups, Rowley had to assume that each averted CF birth was replaced by a 
healthy pregnancy.   This raises a considerable ethical issue on how we value 
and measure the life of the unborn child.    
 
The  studies  that  conducted  cost  effectiveness  analysis  and  reported  their 
finding  in  terms  of  ICER  (e.g.  cost  per  carrier  couple  identified),  provide 
decision  makers  with  potentially  valuable  information  about  the  most 
efficient type of screening program, but not about whether or not a screening 
program  is  expected  to  bring  net  economic  benefits.      This  is  because  the 
outcome  measures  reported  in  these  studies  only  allow  for  comparison 
between other CF programs and not across other health care programs.   It 
presumes that the decision to implement a CF screening program has already 
been taken and the only decision left is to determine what type of screening 
program. 
 
It is inevitable that the ICER found in the international literature will vary 
from one setting to another.  For one, different countries face different prices 
for their health care costs.  Yet, in examining the studies in more detail we 
discovered  that  the  variations  in  ICER  are  to  a  large  degree  due  to  study 
methods and assumptions and not solely to a difference in cost structures.  
Some studies limited their cost analysis to those of the health care system, 
whereas others took a broader view and included lost productivity.  Some 
studies included discount rates to adjust future costs, others did not.   To a 
large degree such variations can be taken into account when modelling the 
cost and consequences of CF screening.   
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However, large parts of the ICER variation were driven by differences in the 
screening participation rates, the reproductive choices made by prospective 
parents and sensitivity and specificity of the tests.  Whilst these variations 
could  also  be  taken  into  account  by  using,  for  example,  an  average 
participation  rate,  there  is  no  guarantee  that  this  would  be  an  accurate 
reflection of the true rates.    
 
A useful approach would be to gain a better understanding of which model 
inputs can be used from the international literature, and which ones are likely 
to vary significantly.  Some of the evidence and assumptions found in the 
literature may be true for the Australian context.  For example, the low rates 
of spontaneous termination as a result of foetal diagnosis are likely to similar 
in  the  Australian  context.    Furthermore,  the  100%  test  accuracy  for  foetal 
diagnosis is likely to hold in the Australian context, as it is offered only after 
both parents are detected as carriers.  One of the limitations of this study is 
that we have restricted our review to economic studies – but for some model 
inputs (such screening participation rates) it may be more useful to broaden 
the scope of the literature search.   
 
With reported high variations in carrier screening test sensitivity for various 
ethnic  groups,  the  relevance  for  using  a  high  test  sensitivity  rates  for 
Australia,  being  a  country  of  multi-racial  population  is  debatable.    In 
Australia, large proportions of the community have almost zero risk of CF 
and indicates that a 12 mutation panel could detect 85 % of possible severe 
mutations  across  the  Australian  population  (Massie,  Delatycki  et  al.  2005).  
Hence, in developing an economic model for the Australian context, we need 
to be explicit of the ethnic composition of the screening target group, and take 
variations in CF carrier incidence into account. 
 
Generally, a straight transfer of cost data between settings is likely to lead to 
substantial  errors.    Price  and  care  patterns  are  likely  to  vary  significantly 
between  countries  and  thus  caution  should  be  exercised  in  applying 
international cost data as an input to an Australian model.   A noteworthy 
absence in the majority of studies was the substantial cost of IVF for those 
couples who choose to use pre-implantation genetic diagnosis.  In Australian 
context, this may be a viable option for a large proportion of carrier couples, 
given the extensive public funding available for such services. 
 
Furthermore, there was considerable ambiguity and variation in the literature 
on  how  cost,  and  in  particular  CF  care  costs,  were  derived.    There  were 
variations  in  the  costing  perspectives,  cost  items  included  (and  excluded), 
age-specific,  severity  specific  variations,  and  high  non-hospital  care  costs.  
The evidence points out considering the importance of not using an “average 
patient”  cost,  especially  while  extrapolating  results  to  another  setting.   
Instead, a comprehensive costing of age specific, severity-specific medical and  
  16
non-medical care from a societal perspective should be considered as an input 
to the model.   
 
Definitions of clinical conditions like disease severity may vary in different 
countries and there is no universal consensus on how to stage CF disease. 
Even scoring systems that have been developed to monitor the progress of CF 
have serious limitations (Gaudenz M. Hafen 2006).   This, including measures 
like  pre-symptomatic,  symptomatic  and  severe  irreversible  symptoms 
without  clearly  defining  the  consequences,  makes  generalization  difficult.  
With  such  ambiguity  in  these  definitions,  using  data  from  the  literature 
reinforces our concern of using cost data from other countries.     
 
The variation in the types of outcome measures used in these studies provides 
an  indication  of  the  complexity  of  finding  the  right  measure  for  these 
economic evaluations (Hall, Viney et al. 1998).  The use of comparators should 
also be context specific.  For example, newborn screening for CF has been 
sporadic  elsewhere  (e.g.    Colorado,  Wisconsin)  but  Australia  and  New 
Zealand do have national new-born screening for CF.  This means that we 
should compare CF community screening against new-born screening rather 
than comparing to ‘no program at all’.    
 
This review has identified the gaps and limitations of generalising the existing 
evidence  to  the  Australian  context.    It  has  highlighted  some  important 
weaknesses  in  generalizing  the  findings  or  for  that  matter,  to  use  existing 
evidence to model the costs and consequences from one setting to another.  At 
the same time we have attempted to make best use of the existing evidence by 
highlighting  those  aspects  of  the  studies  that  could  be  transferred  to  the 
Australian  context  and  those  that  model  input  where  new  empirical 
information would be of most value.   
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Table 1: Overview of published economic evidence on preconception CF carrier screening versus ‘do nothing’. 
   
Reference  Country  Screening 





Wildhagen MF., et al (1998)  NL  Couple  Primary care  Cost per carrier couple 
detected  UK£80,000   $154,788  
Morris JK.,et al.,(1995)  UK  Couple  Primary care  Cost per carrier couple 
detected  UK£99,550*    $210,453  
Wildhagen MF., et al (1998)  NL  Individual  School  Cost per carrier couple 
detected  UK£85,000    $164,462  
Morris JK.,et al.,(1995)  UK  Individual  Workplace  Cost per carrier couple 
detected  UK£139600    $295,121  
Wildhagen MF., et al (1998)  NL  Step wise  Primary care  Cost per carrier couple 
detected  UK£69,000    $33,504  
Morris JK.,et al.,(1995)  UK  Step wise  Primary care  Cost per carrier couple 
detected  UK£81200   $171,661  
Warren E., et al (2005)  Aus  Individual  School  Cost per carrier detected  A$5,834    $4,340  
Warren E., et al (2005)  Aus  Individual  School  Cost per CF birth avoided  A$530,000    $394,307  
Weijers-Poppelaars F et al.  
(2005)  NL  Step wise  Primary care  Cost per CF birth avoided  US$438,604   $445,933  
Weijers-Poppelaars F et al.  
(2005)  NL  Step wise  Group 
counselling  Cost per CF birth avoided  US$563,316   $572,728  
Wildhagen MF., et al (1998)  NL  Couple  Primary care  Net savings  No    
Wildhagen MF., et al (1998)  NL  Individual  School  Net savings  No    
Verheij JBGM et al (1999)  NL  Step wise  Community and 
primary care  Net savings  Yes    
Weijers-Poppelaars F et al.  
(2005)  NL  Step wise  Group 
counselling  Net savings  No    
Wildhagen MF., et al (1998)  NL  Step wise  Primary care  Net savings  Yes    
Weijers-Poppelaars F et al.  
(2005)  NL  Step wise  Primary care  Net savings  No    
* Midpoint              
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Table 2: Overview of published economic evidence on prenatal CF carrier screening versus ‘do nothing’. 
Reference  Country  Screening 





Cuckle HS.  et al.(1995)  UK  Couple  Clinics and 
general practice  Cost per affected pregnancy  UK£75,000*  $158,553 
Cuckle HS., et al.(1995)  UK  Step wise  Clinics and 
general practice  Cost per affected pregnancy  UK£65,000*  $137,413 
Lieu TA.  et al.(1994)  US  Step wise  Not stated  Cost per high-risk pregnancy 
identified^  US$82,000  $110,855 
Wildhagen MF., et al (1998)  NL  Couple  Primary care  Cost per carrier couple 
detected   UK£70,000   $134,073 
Morris JK.,et al.,(1995)  UK  Couple  Hospital  Cost per carrier couple 
detected  UK£35,700  $75,471 
Morris JK.,et al.,(1995)  UK  Individual  Primary care  Cost per carrier couple 
detected  UK£40,800   $86,253 
Wildhagen MF., et al (1998)  NL  Step wise  Primary care  Cost per carrier couple 
detected  UK£58,000   $111,089 
Morris JK.,et al.,(1995)  UK  Step wise  Primary care  Cost per carrier couple 
detected  UK£40,900   $86,464 
Asch DA, et al (1998)  US  Couple  Not stated  Cost per CF birth averted  US$594,000  $739,581 
Nielsen R et al (2002)  Den  Step wise  Primary care  Cost per CF birth averted  DKK2,771,262  $386,773 
Asch DA, et al (1998)  US  Step wise  Not stated  Cost per CF birth averted  US$367,000  $456,946 
Rowley PT.  et al.(1998)  US  Stepwise  Hospital/clinic  Cost per CF birth averted  US$1,322,376  $1,608,861 
Rowley PT.  et al.(1998)  US  Stepwise  Hospital/clinic  Cost per QALY  US$8,290  $10,086 
Wildhagen MF., et al (1998)  NL  Couple  Primary care  Net savings  Yes    
Wildhagen MF., et al (1998)  NL  Step wise  Primary care  Net savings  Yes    
Doyle NM et al (2003)  US (Mex)  Step wise  Not stated  Net savings  No    
Nielsen R et al.  (2002)  Den  Step wise  Primary care  Net savings  Yes    
Lieu TA.  et al.(1994)  US  Step wise  Not stated  Net savings  No    
Vintzileos AM., et al (1998)  US  Step wise  Not stated  Net savings  Yes    
Ginsberg G., et al.  (1994)  Israel  Step wise  Clinics  Net savings  No**    
Rowley PT.  et al.(1998)  US  Step wise  Hospital/clinic  Net savings  No**    
* Midpoint  ** There were net savings when the benefits of screening of subsequent pregnancies and productivity changes were taken into account 
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Table. 3: Reproducibility Assessment of Preconception and Prenatal Studies 
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Table. 4a: Probabilities on Screening Uptake Rates (Preconception Screening) 
Study     Probability Used 
Sensitivity 
Analysis (SA)  Range of SA  Evidences 




Warren E., et al (2005) 
Others - Schools 
0.30  Yes  0.0 - 0.40  School Screening Program 
GP Consultation   0.35     0.18 - 0.53 
Weijers-Poppelaars F et al. 
(2005) 
Group Educational Session  0.20     0.10 - 0.30 
Assumptions from pilot study 
(with allowances for mass 
media campaign for 
screening) 
Verheij JBGM et al (1999)  General Population  0.25, 0.50, 0.75, 
1.00  Yes 
0.25, 0.50, 0.75, 
1.00  Published Studies 
General Population 
0.50  Yes 
Assumption that absence of 
preconeptional consultative 
system would result in lesser 
uptake 
Wildhagen MF., et al (1998) 
School Screening  0.85  Yes 




Letters - GPs  0.10  Yes  Reduced  by 5% 
Opportunistic 
Encouragement - GPs  0.68  Yes  Reduced  by 5% 
Morris JK.,et al.,(1995) 
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Table. 4b: Probabilities on Screening Uptake Rates (Prenatal Screening) 
Study     Probability Used 
Sensitivity 
Analysis (SA)  Range of SA  Evidences 
Doyle NM., & Gardner 
MO.(2003)   Pregnant Women  1.00  No     Published Studies 
Pregnant Women  0.80  Yes  Reduced to 0.60 
Nielsen R et al. (2002) 
Partners  0.94  No    
Published Studies 
Pregnant Women  0.57  Yes  0.20 - 1.00 
Rowley PT. et al.(1998) 
Partners  0.85  Yes  0.05 - 1.00 
Trial data and published 
studies 
Wildhagen MF., et al (1998)  General Population  0.90  Yes 




Pregnant Women  1.00  Yes  0.20 - 1.00(Whites), 
0.50 - 0.78(Others)  Published Studies 
Vintzileos AM., et al (1998) 
Partners  1.00  No       
Pregnant Women 
(Stepwise)  0.75  Yes  0.55 - 0.95  Pilot study data & published 
studies 
Partners(Stepwise)  1.00  No     Assumptions  Cuckle HS., et al.(1995) 
Couple Screening  1.00  Yes.  Reduced by 10 -
20%  Assumptions 
Pregnant Women 
(Stepwise)-Hospital  0.729  No    
Partners(Stepwise)-Hospital  0.991  No    
Couple Screening-Hospital  0.67  Yes  Reduced  by 5% 
Pregnant Women 
(Stepwise)-GP  0.868  No    
Partners(Stepwise)-GP  1.00  No    
Morris JK.,et al.,(1995) 
Couple Screening-GP  0.816  Yes  Reduced  by 5% 
Published Studies 
Lieu TA. et al.(1994)  Couple Screening  0.78  Yes  0.30 - 1.00  Published Studies 
Pregnant Women  0.50  No    
Ginsberg G., et al. (1994) 
Partners  1.00  No    
Assumption based on similar 
programmes & published 
studies 
Garbner AM., & Fenerty JP 
(1991)  Couple Screening  1.00  No     Assumptions 
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Table. 4c: Probabilities on Reproductive Choices (Preconception) 
Study     Probability Used 
Sensitivity 
Analysis (SA)  Range of SA  Evidences 
Refrain from children  0.25  Yes  0.10 – 0.40  
Prenatal Diagnosis rate  0.75  Yes   0.60 – 0.90 
Termination rate(CF foetus)  0.95  Yes   0.90 – 1.00 
Weijers-Poppelaars F et al. 
(2005) 
Iatrogenic termination 
(during diagnosis)  0.0075  No    
Refrain from children  0.15  No    
Prenatal Diagnosis rate  0.85  No    
Termination rate(CF foetus)  0.80  No    
Verheij JBGM et al (1999), 
Wildhagen MF., et al (1998) 
Iatrogenic termination 
(during diagnosis)  0.0075  No    
Conservative assumptions of 
estimates from literature, due 
to small numbers and 
suspected selection bias 
Asch DA, et al (1998)  Iatrogenic termination 
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Table. 4d: Probabilities on Prenatal Diagnosis Acceptance and Reproductive Decisions 
Study     Probability Used 
Sensitivity 
Analysis (SA)  Range of SA  Evidences 
Prenatal Diagnosis  0.75  Yes  0.00 - 1.00  Doyle NM., & Gardner 
MO.(2003)   Termination Rate  0.75  Yes  0.00 - 1.00 
Published Studies 
Prenatal Diagnosis  1.00  No    
Nielsen R et al. (2002) 
Termination Rate  0.95  Yes  Reduced to 0.80 
Published Studies 
Prenatal Diagnosis  0.80  Yes  0.50 - 1.00  Trial data 
Termination Rate  0.75  Yes  0.50 - 1.00  Trial data  Rowley PT. et al.(1998) 
Foetus Replacement  1.00  Yes  0.00 - 1.00  Published Studies 
Prenatal Diagnosis  1.00  No    
Vintzileos AM., et al (1998) 
Termination Rate  0.50 & 1.00  Yes  0.50 & 1.00 
Assumptions 
Prenatal Diagnosis  0.80  No     Assumptions 
Termination Rate  0.30  Yes  0.00 - 1.00  Published Studies 
Iatrogenic termination (CVS )  0.013  No     Published Studies  Lieu TA. et al.(1994) 
Iatrogenic termination 
(amniocentesis)  0.005  No     Published Studies 
Prenatal Diagnosis  0.971  No    
Termination Rate  0.92  Yes  Reduced to 0.80 & 
0.60  Ginsberg G., et al. (1994) 
Iatrogenic termination (CVS )  0.012  No    
Assumption based on similar 
programmes & published 
studies 
Prenatal Diagnosis  1.00  No    
Termination Rate  1.00  No     Garbner AM., & Fenerty JP 
(1991) 
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Table. 4e: Probabilities on Screening Test Sensitivity & Specificity 
Study     Probability Used 
Sensitivity 
Analysis (SA)  Range of SA  Evidences 
Sensitivity- Ashkenazi  0.95  Yes  Reduced to 0.28 
Sensitivity - CNJ  0.75  Yes  Reduced to 0.70 
Sensitivity - Others  0.05  No    
Warren E., et al (2005) 
Specificity  0.9999  No    
Expert opinion on the 
basis of specific assay 
used 
Sensitivity(Stepwise - Women)  0.95  No    
Sensitivity(Stepwise - Partner)  0.98  No    
Couple  0.98  No    
Weijers-Poppelaars F et al. 
(2005) 
Specificity  1.00  No    
Not clear but could be from 
pilot studies and published 
literature 
Doyle NM., & Gardner 
MO.(2003)   Sensitivity  0.90  Yes  0.00 - 0.90  Published Studies 
Sensitivity  0.90  Yes  Increase by 1% 
Nielsen R et al. (2002) 
Specificity  1.00  No    
Published Studies 
Sensitivity - ASO Hybridisation  0.90  No    
Verheij JBGM et al (1999) 
Sensitivity - DGGE  0.98  No    
Published Studies 
Rowley PT. et al.(1998)  Sensitivity  0.85  Yes  0.50 - 1.00  Trial data 
Wildhagen MF., et al (1998)  Sensitivity   0.855  No     Published Studies 
Sensitivity - Whites  0.90  Yes  0.80 - 1.00 
Sensitivity - Black  0.75  Yes  0.70 - 1.00 
Sensitivity - Asians  0.30  Yes  0.25 - 1.00 
Vintzileos AM., et al (1998) 
Sensitivity - Hispanics  0.57  Yes  0.50 - 1.00 
Published Studies 
Cuckle HS., et al.(1995)  Sensitivity  0.80  Yes 
0.70 - 0.85(∆F508),           
0.80 - 0.95 
(multimutation) 
Published Studies 
Sensitivity  0.85  Yes  0.50 - 1.00 
Lieu TA. et al.(1994) 
Specificity  0.9999  No    
Published Studies 
Sensitivity  0.941  Yes  0.70 - 1.00  Published Studies  Ginsberg G., et al. (1994) 
Specificity  0.99  No     Assumed errors 
Sensitivity  0.99  Yes  0.90 - 1.00  Garbner AM., & Fenerty JP 
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